Background/aim: To evaluate the impact of development of nivolumab monotherapy-induced immune-related adverse events (irAEs) and continuing nivolumab with irAEs on the survival of patients with gastric cancer (GC).

Patients And Methods: Patients with unresectable advanced GC and recurrence after curative resection who received nivolumab monotherapy were included in the study. Survival was compared between patients who did and did not develop irAEs, and between those who continued and discontinued treatment due to irAEs.

Results: Of 110 GC patients, 22 developed irAEs. Grade ≥3 IrAEs included rash and diarrhoea associated with enteritis. Progression-free and overall survival (OS) were significantly better in patients with irAEs than in those without. The overall survival of patients who continued treatment despite irAEs was better than that of those who discontinued treatment.

Conclusion: irAE development was associated with better survival in patients with GC who received nivolumab monotherapy. Continuing nivolumab with appropriate treatment in GC patients with irAEs may improve survival.

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.15626DOI Listing

Publication Analysis

Top Keywords

survival patients
12
patients
9
immune-related adverse
8
adverse events
8
gastric cancer
8
iraes
8
continuing nivolumab
8
iraes survival
8
received nivolumab
8
nivolumab monotherapy
8

Similar Publications

Background: Clinical characteristics and outcomes of carbapenem-resistant Enterobacterales (CRE) infection and colonization have rarely been reported in patients with severe burns, who are prone to severe bacterial infections. This study aimed to evaluate clinical characteristics and outcomes of CRE infection and colonization in patients with severe burns.

Methods: The characteristics of 106 episodes of CRE acquisition (infection or colonization) in 98 patients with severe burns were evaluated by a retrospective medical record review.

View Article and Find Full Text PDF

Comprehensive analysis of the interaction microbiome and prostate cancer: an initial exploration from multi-cohort metagenome and GWAS studies.

J Transl Med

January 2025

Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, Wuhan, Wuhan, 430030, P.R. China.

Introduction: Prostate cancer is one of the most common cancers in the United States with a high mortality rate. In recent years, the traditional opinion about prostate microbiome was challenged. Although there still are some arguments, an escalating number of researchers are shifting their focus toward the microbiome within the prostate tumor environment.

View Article and Find Full Text PDF

Background: Aortic dissection occurs rarely during pregnancy but carries a significantly high vital risk for both the mother and the fetus. Early diagnosis and treatment are critical for a successful outcome.

Case Presentation: A 32-year-old pregnant woman at 31 weeks of gestation began experiencing shortness of breath, chest pain, and palpitations, which were attributed to an anxiety disorder she had been previously diagnosed with.

View Article and Find Full Text PDF

Advancing cancer therapy with custom-built alternating electric field devices.

Bioelectron Med

January 2025

School of Pharmacy, Biodiscovery Institute & Boots Science Building, University of Nottingham, Nottingham, NG7 2RD, UK.

Background: In glioblastoma (GBM) therapy research, tumour treating fields by the company Novocure™, have shown promise for increasing patient overall survival. When used with the chemotherapeutic agent temozolomide, they extend median survival by five months. However, there is a space to design alternative systems that will be amenable for wider use in current research.

View Article and Find Full Text PDF

Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology.

Radiat Oncol

January 2025

Department of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany.

Background: Medulloblastoma is the most common malignant pediatric brain tumor, typically treated with normofractionated craniospinal irradiation (CSI) with an additional boost over about 6 weeks in children older than 3 years. This study investigates the sensitivity of pediatric medulloblastoma cell lines to different radiation fractionation schedules. While extensively studied in adult tumors, these ratios remain unknown in pediatric cases due to the rarity of the disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!